Barbara K. Finck - Mar 16, 2022 Form 4/A - Amendment Insider Report for Forte Biosciences, Inc. (FBRX)

Role: Director
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol: FBRX
Transactions as of: Mar 16, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 5/16/2022, 04:58 PM
Date Of Original Report: Mar 18, 2022
Next filing: May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Stock Option (right to buy)	Award	$0	+4.17K		$0.00	4.17K	Mar 16, 2022	Common Stock	4.17K	$1.43	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amended Form 4 is being filed to report an option grant inadvertently omitted from the Form 4 filed on March 18, 2022.
F2	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean March 16, 2022.

Content

This amended Form 4 is being filed to report an option grant inadvertently omitted from the Form 4 filed on March 18, 2022.

Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean March 16, 2022.